Iris Nagelmeier

866 total citations
12 papers, 650 citations indexed

About

Iris Nagelmeier is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Iris Nagelmeier has authored 12 papers receiving a total of 650 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Iris Nagelmeier's work include HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Iris Nagelmeier is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Iris Nagelmeier collaborates with scholars based in Germany, Italy and United States. Iris Nagelmeier's co-authors include Josef Rüschoff, Hans Kreipe, Gustavo Baretton, W. Schlake, Manfred Dietel, Heinz Höfler, Geneviève Monges, Marie‐Pierre Chenard, Frédérique Penault‐Llorca and Susanne Arbogast and has published in prestigious journals such as Journal of Clinical Pathology, Oncotarget and Modern Pathology.

In The Last Decade

Iris Nagelmeier

12 papers receiving 638 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Iris Nagelmeier Germany 8 525 366 224 133 102 12 650
Feng-yi Feng China 8 450 0.9× 345 0.9× 109 0.5× 177 1.3× 58 0.6× 35 673
Yoshikane Nonagase Japan 11 390 0.7× 204 0.6× 185 0.8× 125 0.9× 103 1.0× 19 515
Takahiro Kamio Japan 9 775 1.5× 600 1.6× 313 1.4× 169 1.3× 82 0.8× 20 1.1k
Michele Prisciandaro Italy 15 566 1.1× 270 0.7× 83 0.4× 157 1.2× 146 1.4× 49 761
Shigekazu Ohoyama Japan 10 398 0.8× 330 0.9× 190 0.8× 203 1.5× 43 0.4× 13 654
W. Fett Germany 9 421 0.8× 173 0.5× 129 0.6× 92 0.7× 298 2.9× 13 707
Kwang Hyuck Lee South Korea 21 815 1.6× 413 1.1× 109 0.5× 160 1.2× 249 2.4× 47 1.1k
Meiting Fu China 10 166 0.3× 232 0.6× 102 0.5× 79 0.6× 59 0.6× 13 442
Catherine Chodkiewicz United States 8 387 0.7× 269 0.7× 68 0.3× 159 1.2× 109 1.1× 10 644
T Hirota Japan 12 399 0.8× 135 0.4× 143 0.6× 202 1.5× 166 1.6× 25 670

Countries citing papers authored by Iris Nagelmeier

Since Specialization
Citations

This map shows the geographic impact of Iris Nagelmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Nagelmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Nagelmeier more than expected).

Fields of papers citing papers by Iris Nagelmeier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Nagelmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Nagelmeier. The network helps show where Iris Nagelmeier may publish in the future.

Co-authorship network of co-authors of Iris Nagelmeier

This figure shows the co-authorship network connecting the top 25 collaborators of Iris Nagelmeier. A scholar is included among the top collaborators of Iris Nagelmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iris Nagelmeier. Iris Nagelmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Rüschoff, Josef, Michael Friedrich, Iris Nagelmeier, et al.. (2022). Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 481(5). 685–694. 46 indexed citations
2.
Rüschoff, Josef, Iris Nagelmeier, Bharat Jasani, & Oliver Stoß. (2020). ISH-based HER2 diagnostics. Der Pathologe. 42(S1). 62–68. 5 indexed citations
3.
Stoß, Oliver, Andreas H. Scheel, Iris Nagelmeier, et al.. (2015). Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data. Modern Pathology. 28(12). 1528–1534. 42 indexed citations
4.
Styczen, Hanna, Iris Nagelmeier, Tim Beißbarth, et al.. (2015). HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. Oncotarget. 6(17). 15065–15076. 21 indexed citations
5.
Derer, Stefanie, Sven Berger, Tanja Schneider‐Merck, et al.. (2012). Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression. Neoplasia. 14(3). 190–IN7. 18 indexed citations
6.
Rüschoff, Josef, Manfred Dietel, Gustavo Baretton, et al.. (2010). HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 457(3). 299–307. 368 indexed citations
7.
Rüschoff, Josef, Iris Nagelmeier, Gustavo Baretton, et al.. (2010). Her2-Diagnostik beim Magenkarzinom: Was ist anders im Vergleich zum Mammakarzinom?. Der Pathologe. 31(3). 208–217. 1 indexed citations
8.
Rüschoff, Josef, Iris Nagelmeier, Gustavo Baretton, et al.. (2010). Her2-Diagnostik beim Magenkarzinom. Der Pathologe. 31(3). 208–217. 33 indexed citations
9.
Rüschoff, Josef, et al.. (2009). Aktuelles zur ErbB2-Diagnostik beim Mammakarzinom. Der Pathologe. 30(2). 147–155. 3 indexed citations
10.
Varella‐Garcia, Marileila, Joachim Diebold, David A. Eberhard, et al.. (2009). EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. Journal of Clinical Pathology. 62(11). 970–977. 96 indexed citations
11.
Brugger, W., et al.. (2009). 9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC. European Journal of Cancer Supplements. 7(2). 559–559. 13 indexed citations
12.
Roth, Christian, Timo Gaiser, Iris Nagelmeier, Josef Rüschoff, & A. Ferbert. (2007). Neurofibromatose Typ I und Megadolichobasilaris. Der Nervenarzt. 78(10). 1195–1199. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Feng-yi Feng Breakdown of academic impact, for papers by Yoshikane Nonagase Breakdown of academic impact, for papers by Takahiro Kamio Breakdown of academic impact, for papers by Michele Prisciandaro Breakdown of academic impact, for papers by Shigekazu Ohoyama Breakdown of academic impact, for papers by W. Fett Breakdown of academic impact, for papers by Kwang Hyuck Lee Breakdown of academic impact, for papers by Meiting Fu Breakdown of academic impact, for papers by Catherine Chodkiewicz Breakdown of academic impact, for papers by T Hirota
Rankless by CCL
2026